Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma
Status:
Completed
Trial end date:
2018-11-30
Target enrollment:
Participant gender:
Summary
A phase II, single-arm, open-label, multicenter study to assess the efficacy and safety of
Surufatinib as a second-line treatment in patients with surgically unresectable or metastatic
biliary tract carcinoma